Equity Overview
Price & Market Data
Price: $2.86
Daily Change: +$0.12 / 4.20%
Daily Range: $2.82 - $2.86
Market Cap: $267,364,208
Daily Volume: 1,148
Performance Metrics
1 Week: 16.60%
1 Month: -9.87%
3 Months: 34.98%
6 Months: 20.70%
1 Year: 106.0%
YTD: 43.46%
Company Details
Employees: 104
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.